| dc.contributor.author | Deliv, Inga | |
| dc.date.accessioned | 2026-02-20T10:57:50Z | |
| dc.date.available | 2026-02-20T10:57:50Z | |
| dc.date.issued | 2025 | |
| dc.identifier.citation | DELIV, Inga. From symptom to functionality: modern solutions for the anxious patient. In: Satellite Conference “New horizons in mental health” organized within the Anniversary Congress “80 Years of Innovation in Health and Medical Education” of Nicolae Testemițanu State University of Medicine and Pharmacy, 20-23 October 2025, Chisinau, Republic of Moldova. Abstract book/ presidents of the scientific committee: Emil Ceban, Jana Chihai. Chișinău: [s. n.], 2025, p. 65. ISBN 978-5-86654-547-6. | en_US |
| dc.identifier.isbn | 978-5-86654-547-6 | |
| dc.identifier.uri | https://sanatatemintala.md/images/Abstract%20BOOK%202025.pdf | |
| dc.identifier.uri | https://repository.usmf.md/handle/20.500.12710/32615 | |
| dc.description.abstract | Anxiety disorders represent one of the most prevalent mental health conditions worldwide, often leading to significant impairment in social and occupational functioning. Modern management strategies focus not only on symptom reduction but also on restoring functional capacity and improving quality of life. A synthesis of recent clinical-scientific studies (2018–2024) was conducted, focusing on pharmacological interventions with anxiolytic action and favorable tolerability profiles. Anxiety disorders exert a profound global burden, affecting up to 20% of the population over a lifetime and ranking among the leading contributors to years lived with disability. Beyond emotional suffering, chronic anxiety is associated with significant somatic symptoms, cardiovascular disturbances, cognitive decline, and increased utilization of medical services. These factors impair social functioning and diminish overall quality of life. Pharmacological management remains a cornerstone of treatment, particularly in moderate to severe cases. Short- to medium-acting benzodiazepine derivatives demonstrate rapid anxiolytic effects through potentiation of GABAergic neurotransmission, leading to improved emotional regulation, normalization of sleep, and restoration of daily functioning. Contemporary agents with reduced hepatic accumulation and lower dependence potential provide a safer clinical profile, especially when administered for limited periods under strict medical supervision. Comparative studies highlight that combining pharmacotherapy with cognitive-behavioral therapy results in greater functional recovery and lower relapse rates than either modality administered alone. Furthermore, modern clinical guidelines emphasize early intervention and an individualized approach to balance efficacy and safety. The integrative approach that links neurochemical stabilization with psychotherapeutic adaptation promotes durable recovery, enhances patient autonomy, and aligns with the modern paradigm of functionality-centered psychiatric care. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Universitatea de Stat de Medicină și Farmacie "Nicolae Testemiţanu" din Republica Moldova, Ministerul Sănătăţii al Republicii Moldova | en_US |
| dc.relation.ispartof | Satellite Conference “New horizons in mental health” organized within the Anniversary Congress “80 Years of Innovation in Health and Medical Education” of Nicolae Testemițanu State University of Medicine and Pharmacy, 20-23 October 2025, Chisinau, Republic of Moldova | en_US |
| dc.title | From symptom to functionality: modern solutions for the anxious patient | en_US |
| dc.type | Other | en_US |